The raised guidance across GAAP EPS, Adjusted EPS, and cash flow from operations signals improving operational trends, particularly in the Health Care Benefits segment's margin recovery. Monitor the Q4 earnings call for updates on medical cost trends and the impact of GLP-1 drug utilization on pharmacy margins.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 4 $79.96entry
- T+1 · 12d ago +1.71%α +6.12% · $81.33
- T+5 · 6d ago +11.96%α +12.87% · $89.52
- T+8 · todayOpen
- T+20 · in 16d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
CVS Health reported Q3 2026 revenue of $108.4B (+5.4% YoY) and Adjusted EPS of $2.09, above the consensus estimate of $1.65. The company raised full-year 2026 guidance: GAAP diluted EPS to at least $6.98 (from $6.84-$7.04), Adjusted EPS to at least $8.20 (from $7.90-$8.10), and cash flow from operations to at least $15.5B (from at least $11.5B). The Health Care Benefits segment continued its margin recovery, with MBR improving 150 bps YoY to 91.3%.
Key Financial Metrics
Key Facts
- Q3 2026 total revenues of $108.4B, up 5.4% YoY from $102.9B
- Q3 2026 GAAP diluted EPS of $1.68 vs a loss of $3.13 in the prior year
- Q3 2026 Adjusted EPS of $2.09, up from $1.60 YoY
- Full-year 2026 GAAP diluted EPS guidance raised to at least $6.98 from $6.84-$7.04
- Full-year 2026 Adjusted EPS guidance raised to at least $8.20 from $7.90-$8.10
- Full-year 2026 cash flow from operations guidance raised to at least $15.5B from at least $11.5B
- Health Care Benefits segment MBR improved to 91.3% from 92.8% YoY
- Year-to-date cash flow from operations of $15.3B
- Adjusted operating income increased 21.2% to $4.2B
- Health Services segment revenue grew 9.5% to $54.0B
Financial Impact
Q3 revenue $108.4B vs consensus $104.69B; Adjusted EPS $2.09 vs consensus $1.65; full-year guidance raised across all key metrics
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Health Care Benefits | $36.9B | +2.4% |
| Health Services | $54.0B | +9.5% |
| Pharmacy Consumer Wellness | $35.5B | -2.0% |
Risk Factors
- Continued elevated medical cost trends and macro headwinds cited in cautious outlook
- Pharmacy Consumer Wellness segment revenue declined 2.0% YoY due to drug pricing pressure
- Omnicare guarantee liability of $193M recorded in Q3
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0000064803-26-000107 |
| Document: cvs-20261104.htm | 0000064803-26-000107 |
| Document: 0000064803-26-000107-index-headers.html | 0000064803-26-000107 |
| Document: 0000064803-26-000107-index.html | 0000064803-26-000107 |
| Document: 0000064803-26-000107.txt | 0000064803-26-000107 |
| 8-K Data (Synthetic) | 0000064803-26-000107 |
Track record
25 reports on CVS
4 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +32.33% at T+60 after the Apr 8, 2026 report. 6 of 8 went positive at some point.
Filters
- Nov 13, 20264d ago Court Ruling Neutral 3/10 No price data
- Nov 6, 202610d ago Insider Buy Bullish 4/10 Entry $85.25 Now $88.59 +3.92% settles Dec 8
- Nov 4, 202612d ago 8-K Neutral 6/10 Entry $79.96 Now $88.59 +10.79% settles Dec 3
- Nov 4, 202612d ago 8-K Bullish 6/10 Viewing Entry $79.96 Now $88.59 +10.79% settles Dec 3
- Oct 26, 202621d ago Institutional Cluster Neutral 3/10 Entry $92.53 Now $88.59 −4.26% settles Nov 23
- Oct 15, 20264w ago Press Release Neutral 2/10 Entry $92.58 to $89.79 Now $88.59 −4.31% ▼ −3.01% −1.11% vs SPY
- Sep 30, 20266w ago Press Release Neutral 2/10 Entry $85.20 to $90.33 Now $88.59 +3.98% ▲ +6.02% +5.32% vs SPY
- Aug 5, 202614w ago 8-K Bullish 8/10 Entry $99.12 to $97.23 Now $88.59 −10.62% ▼ −1.91% −1.31% vs SPY
- Jul 10, 202618w ago Press Release Neutral 2/10 Entry $104.15 to $95.46 Now $88.59 −14.94% ▼ −8.35% −10.77% vs SPY
- Jun 29, 202620w ago Court Ruling Bullish 5/10 Entry $103.58 to $107.74 Now $88.59 −14.47% ▲ +4.02% +4.30% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers